Skip Ribbon Commands
Skip to main content
 


M14-212 A Phase 2 Study of ABT-199 in Subjects with Acute Myelogenous Leukemia (AML)


Trial Focus

Leukemia/Myelodysplasia

Objective

         This is a clinical trial of ABT-199 that will be administered by mouth, which is investigational.

IRB Protocol #

13-2463

Trial Status

Archived

Principle Investigator

DAN POLLYEA

Sponsor

AbbVie Inc

Contact

DEREK SCHATZ at (720)848-0628 or DEREK.SCHATZ@UCDENVER.EDU

Location

University of Colorado Hospital University of Colorado Hospital

Eligibility and Other Participant Information


What To Expect : A screening period to determine eligibility. A treatment period that can last until your disease worsens or you no longer tolerate study drug treatment. A follow up period will consist of a clinic visit and phone calls. // Eligibility criteria include but are not limited to 18 years or older in patients with AML that is relapsed or refractory, or patients with untreated AML who cannot tolerate standard therapy.Eligibility criteria include but are not limited to 18 years or older in patients with AML that is relapsed or refractory, or patients with untreated AML who cannot tolerate standard therapy.